NuCana (NASDAQ:NCNA) Trading Up 5.8% – Here’s What Happened

NuCana PLC Sponsored ADR (NASDAQ:NCNA)’s stock price shot up 5.8% on Thursday . The stock traded as high as $1.6667 and last traded at $1.63. 18,351 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 54,613 shares. The stock had previously closed at $1.54.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

NuCana Stock Up 5.8%

The stock has a fifty day moving average of $2.08 and a two-hundred day moving average of $3.33. The stock has a market cap of $48,900.00, a price-to-earnings ratio of -0.01 and a beta of 1.79.

Hedge Funds Weigh In On NuCana

A hedge fund recently raised its stake in NuCana stock. FNY Investment Advisers LLC increased its stake in NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,000 shares of the company’s stock after purchasing an additional 6,774 shares during the quarter. FNY Investment Advisers LLC owned 33.33% of NuCana worth $36,000 at the end of the most recent quarter. 44.00% of the stock is currently owned by institutional investors.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.